You are currently viewing Neostigmine Methylsulfate-One Drug Knowledge per Day
Articaine Hydrochloride

Neostigmine Methylsulfate-One Drug Knowledge per Day

  • Post category:News
  • Post comments:0评论
Articaine Hydrochloride
Articaine Hydrochloride
Chemical structural formula: C12H19N2O2CH3O4S
1. Applicability
Anticholinesterase drugs. It is used to antagonize the residual muscle relaxation of non depolarizing muscle relaxants at the end of the operation, for myasthenia gravis, functional flatulence and urinary retention after the operation, etc.
Gelong ammonium bromide compound injection: reversing residual non depolarizing (competitive) neuromuscular blockade
2. Usage and dosage
Commonly used dosage, inject 0.25-1mg subcutaneously or intramuscularly once (1ml: 0.5mg specification half to 2 tubes; 2ml: 1mg specification 1/4 to 1 tube), 1-3 times a day.
Extreme dosage, subcutaneous or intramuscular injection of 1mg (1ml: 0.5mg, 2 tubes; 2ml: 1mg, 1 tube), 5mg per day (1ml: 0.5mg, 10 tubes; 2ml: 1mg, 5 tubes).
3. Product advantages
A cholinesterase inhibitor, approved by the FDA in 2013, for reversing the effects of non depolarizing neuromuscular blockers after surgery;
It has the strongest effect on skeletal muscles and also has a strong stimulating effect on the smooth muscles of the gastrointestinal tract, bladder, and uterus;
Reversible binding with cholinesterase, with fewer side effects and difficulty in crossing the blood-brain barrier. The plasma protein binding rate is low (15% to 25%), and some drugs in the body are hydrolyzed by plasma cholinesterase and excreted from urine in the form of quaternary ammonium alcohol and its original form. The metabolized portion through the liver is excreted from the biliary tract;
More effective recovery of patient’s autonomous urination. Clinical studies have shown that this product combined with intermittent catheterization technology can shorten the establishment of autonomous urination time, reduce the number of catheterization times, and lower the risk of urinary tract infections compared to intermittent catheterization technology treatment for neurogenic bladder. Patients are more receptive to this treatment;
Class A varieties, mainstream muscle relaxant antagonists, with significant sales growth. In 2020, the domestic sales exceeded 300 million yuan, a year-on-year increase of 446.81%. In the first half of 2021, it exceeded the full year of 2020, a year-on-year increase of 190.09%;